Over the last 7 days, the United States market has remained flat, yet it has risen by 5.7% over the past year with earnings forecasted to grow by 13% annually. In this environment, identifying ...

The Diabetes Link organization organized a diabetes tech seminar that brought together individuals with Type 1 diabetes, ...

DexCom (NasdaqGS:DXCM) recently experienced a 14% price increase over the past week. This uptick coincides with the company's announcement of FDA clearance for the Dexcom G7 Continuous Glucose ...

What Johnson & Johnson and Eli Lilly are saying about Trump’s pharmaceutical tariffs, and Dexcom scores FDA approval for its ...

The FDA warned that several hundred units of counterfeit 1-mg semaglutide (Ozempic) were found in the U.S. drug supply chain ...

RBC Capital lowered the firm’s price target on DexCom (DXCM) to $100 from $115 and keeps an Outperform rating on the shares as part of a ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom ( DXCM – Research Report) yesterday and set a price target of $98.00. The company’s shares closed yesterday at $67.39. Filter, ...

The FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for individuals 18 years and older with ...

Dexcom has announced that the U.S. Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring ...

Unprecedented demographic shifts toward an aging population are a defining phenomenon of the 21st century, significantly reshaping the landscape of healthcare delivery and resource allocation. Longer ...

BTIG lowered the firm’s price target on DexCom (DXCM) to $107 from $120 and keeps a Buy rating on the shares as part of a broader research note ...

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of $107.00. The company’s shares closed la ...